Logo

American Heart Association

  11
  0


Final ID: 58

Tenecteplase Beyond 4.5 Hours in Acute Ischemic Stroke: A Systematic Review and Meta-analysis of Clinical Trials

Abstract Body:
Background: Acute ischemic stroke (AIS) is a leading cause of disability worldwide. While intravenous thrombolysis is recommended within 4.5 hours of symptom onset, many patients present beyond this window. Tenecteplase (TNK) has shown to be non-inferior to tissue plasminogen activator (tPA) in early treatment window. However, its efficacy and safety in the extended 4.5 to 24-hour window remain unclear.

Methods: We conducted a systematic review and meta-analysis of published clinical trials investigating TNK administration in AIS patients between 4.5 to 24 hours of symptom onset. PubMed, Cochrane Library, Google Scholar, and ClinicalTrials.gov were searched from inception through June 23rd, 2024. Inclusion criteria were: (1) clinical trials, (2) published in English, (3) full-text available, and (4) TNK administration in AIS or transient ischemic attack patients within 4.5-24 hours of onset. Primary outcomes assessed were functional independence at 90 days (defined as a modified Rankin Scale [mRS] score of 0-2) and ordinal shift in the mRS. Safety outcomes included symptomatic intracranial hemorrhage (sICH). Random-effects models were used to calculate pooled odds ratios (OR) with 95% confidence intervals (CI).

Results: Five clinical trials met inclusion criteria with a total of 1,197 patients (599 TNK, 598 best medical therapy). Mean age was 71 years, with 61.7% males and a median baseline NIHSS of 10. Studies varied in imaging selection criteria, using either MRI DWI/FLAIR mismatch or CTP imaging with different perfusion cut-off values. Additionally, the proportion of patients receiving EVT post-randomization varied among studies. TNK treatment was associated with increased functional independence at 90 days (OR 1.33, 95% CI 1.04-1.70, p=0.02), but no significant difference in overall mRS (standardized mean difference: 0.01, 95% CI -0.37 to 0.39, p=0.969). A trend towards increased sICH with TNK was observed, though not statistically significant (OR 2.16, 95% CI 0.96-5.05, p=0.06).

Conclusion: This meta-analysis suggests that TNK might be safe and effective for AIS patients in the 4.5 to 24-hour time window, potentially offering improved functional outcomes without significant increase in sICH. Future research should focus on conducting large, multicenter randomized controlled trials with refined patient selection criteria and standardized imaging protocols, to more precisely access the risk-benefit profile of TNK in extended time window.
  • Aladawi, Mohammad  ( University of Alabama Medical Center , Birmingham , Alabama , United States )
  • Hataway, Felicia  ( University of Alabama Medical Center , Birmingham , Alabama , United States )
  • Bakradze, Ekaterina  ( University of Alabama Medical Center , Birmingham , Alabama , United States )
  • Lyerly, Michael  ( University of Alabama Medical Center , Birmingham , Alabama , United States )
  • Abuawwad, Mohammad  ( Cairo University , Cairo , Egypt )
  • Taha, Mohammad  ( Cairo University , Cairo , Egypt )
  • Kozaa, Yasmeena  ( Mansoura University , Mansoura , Egypt )
  • Alrubasy, Warda  ( Cairo University , Cairo , Egypt )
  • Hamad, Abdullah  ( Cairo University , Cairo , Egypt )
  • Alhnidi, Fatema  ( Cairo University , Cairo , Egypt )
  • Elfil, Mohamed  ( University of Miami/JHS , Miami , Florida , United States )
  • Najdawi, Zaid  ( University of Nebraska Medical Center , Omaha , Nebraska , United States )
  • Author Disclosures:
    Mohammad Aladawi: DO NOT have relevant financial relationships | Felicia Hataway: DO NOT have relevant financial relationships | Ekaterina Bakradze: DO NOT have relevant financial relationships | Michael Lyerly: DO NOT have relevant financial relationships | Mohammad Abuawwad: DO NOT have relevant financial relationships | Mohammad Taha: DO NOT have relevant financial relationships | yasmeena kozaa: DO NOT have relevant financial relationships | Warda Alrubasy: No Answer | Abdullah Hamad: No Answer | Fatema Alhnidi: No Answer | Mohamed Elfil: DO NOT have relevant financial relationships | Zaid Najdawi: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Acute Treatment: Systemic Thrombolysis and Cerebroprotection Oral Abstracts II

Wednesday, 02/05/2025 , 03:30PM - 04:30PM

Oral Abstract Session

More abstracts on this topic:
Assessment of Limited English Proficiency on Door To Imaging Time

Cort Mark, Sharrief Anjail, Trang Ivan, Nguyen Courtney, Wang Mengxi, Flake-rojas Mariel, Cooksey Gail, Carter Caitlynn, Okpala Munachi, Yamal Jose-miguel

Impact of Door-In-Door-Out Times on Functional Outcomes in Patients with Stroke Transferred for Endovascular Therapy

Royan Regina, Stamm Brian, Giurcanu Mihai, Jauch Edward, Messe Steven, Saver Jeffrey, Prabhakaran Shyam

More abstracts from these authors:
Statewide Collaborative Stroke Education to Enhance Stroke Care: Insight from Statewide Traveling Stroke Symposium

Shoemaker Camella, Crawford William, Lyerly Michael, Bakradze Ekaterina, Gropen Toby, Owens Jacquelyn, Morrison Amanda, Kamal Shaila, Gazi Melissa, Gray Jamie, Floyd Alice, Ross Tabatha, Minor Michael

Endovascular thrombectomy plus intravenous thrombolysis versus endovascular thrombectomy alone in patients with large core infarct

Elfil Mohamed, Malik Amer, Al-mufti Fawaz, Abbas Abdallah, Fountain Hayes, Abdul-hamid Ebrahem, Aladawi Mohammad, Najdawi Zaid, Elmashad Ahmed, Ghaith Hazem, Dawod Giana

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)